Pq.
Nan-Psychophamad
&Rid
Psychiat 1998. Vol. 22, pp. 1129-l 139 Copyright 0 1998 Elsetier Science Inc. Printed
ELSEVIER
in the USA. All rights reserved 0278.5%X6/98 $19.00 + .OO
PI1 SO278-5846(98)00065-7
CHRONICAL HALOPERIDOL AND CLOZAPINE TREATMENT IN RATS: DIFFERENTIAL RNA DISPLAY ANALYSIS, BEHAVIORAL STUDIES AND SERUM LEVEL DETERMINATION VIOLA FISCHER’, ULRICH SCHMITT’, HARALD WEIGMANN’. BORIS v. KELLER’, STEFAN REUSS’. CHRISTOPH HIEMKE’ and NORBERT DAHMEN’ Departments
of Psychiatry’
and Anatomy’, University
(Final form,
August
of Mainz, Mainz, Germany
1998)
Abstract Fischer, Viola, Ulrich Schmitt, Harald Weigmann, Boris v. Keller, Stefan Reuss, Christoph Hiemke and Norbert Dahmen: Chronical Haloperidol and Clozapine Treatment in Rats: Differential RNA Display Analysis, Behavioral Studies and Serum Level Determination. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1998, 2. pp. 1129-l 139. 0 1998 Elsevier Science Inc. 1. 2.
3.
4.
Adult, female rats were treated orally for 23 days with 1.6 mgikg haloperidol or 36 mg/kg clozapine per day, to study chronic effects of the two neuroleptics. At five time points during the neuroleptic treatment, animal behavior was recorded in an open field and locomotive activity was analysed. At the end of the experiment, rats were decapitated, blood samples were collected and serum concentrations of haloperidol and clozapine were determined by a radioreceptor or HPLC assay, respectively. RNA was isolated from each brain, without cerebellum, and subjected to differential RNA display. Mean serum concentrations were 8 ngiml for haloperidol and 21 ngiml for clozapine. Analysis of open field behavior showed that haloperidol and clozapine decreased the total distance moved and the velocity as measures of the overall activity, whereas the number of rearings and the number of entries into the center, reflecting risk assessment behavior, were differentially affected. Three neuroleptic-regulated gene fragment bands were identified in differential RNA display experiments. Two gene fragments of 281 bp and 266 bp were sequenced. We conclude that our study design that used behavioral, pharmacokinetic and molecular analysis increase the likelihood of finding relevant molecular events underlying the pharmacotherapeutic effects of neuroleptics in animal models.
Keywords:
behavioral
studies, chronical treatment, clozapine, differential
RNA display, haloperidol.
Introduction Neuroleptics
are a chemically
such as schizophrenia.
diverse group of compounds
used to treat various psychiatric
disorders
Based on their clinical side effects, they are divided into two groups, i.e. typical
and atypical neuroleptics.
Haloperidol
is the most common typical neuroleptic 1129
(Settle and Ayd, 1983;
1130
V. Fischer et aL
Janssen et al., 1959). Unwanted dyskinesia
extrapyramidal
can appear during the treatment
prototype
of an atypical neuroleptic
Kerwin, 1994). Antipsychotic
side effects such as dystonia, parkinsonism
with haloperidol.
The neuroleptic
that causes no extrapyramidal
medications
clozapine
are believed to exert at least a part of their therapeutic
has low affinity for dopamine D2 receptors in vitro (Bartholini,
receptor
related side effects.
represents
the
side effects (Weiner et al., 1996;
by blocking one or more of the five dopamine receptors that have been distinguished
with low D2 receptor occupancy
and tardive
effects
so far. Clozapine
1976) and clinical response is associated
(Pilowsky et al., 1992), a fact that may account for the absence of D2
After cloning
the D4 dopamine
receptor
it has become
apparent
that
clozapine binds to the D4 receptor with an affinity 10 times higher than to the D2 receptor (van To1 et al., 1991), differentiating
it from the typical antipsychotic
drugs. Haloperidol
binds with high affinity to
the D2 receptor but also has considerable
affinity to the D3 and D4 dopamine receptors. In vivo binding
studies in rat brain show that clozapine
in therapeutically
binding sites, whereas haloperidol and Andersen.
doses occupies
also Dl receptor
binds to D2-like receptors (Leysen et al., 1992; Nielsen
1992).
To date, no comprehensive molecular
exclusively
effective
model
level. The time lag between
targets, the neurotransmitter
receptors,
exists
explaining
the immediate
the clinical interaction
efficacy
of neuroleptics
of neuroleptics
and the relief from psychotic
symptoms
with their primary suggests
that further
processes are relevant. Among the discussed processes modulatory effects on gene expression particular importance
or clozapine
administered
survey of genes influenced
in a pharmacologically
locomotive
treatment,
the animal behavior
activity. At the end of the treatment,
RNA display consequence
was used as a method
or clozapine.
was recorded
identify
relevant dose in
At five time points
in an open field to analyse the
serum concentrations
to systematically
by chronical treatment with
and behaviorally
the rat model. Rats were treated orally for 23 days with haloperidol during the neuroleptic
may be of
(Nestler, 1997).
This study was set out to initiate a systematic either haloperidol
on the
were monitored
changes
and differential
in gene expression
as a
of the chronical treatment.
Methods Studv Design For this study, nine adult, two month old female Sprague Dawley rats, ranging in weight from 200-230 g, were used. Animals were divided into three groups with n=3, i.e. a control, a haloperidol clozapine treated group. Rats were decapitated
after 23 days of treatment.
treated and a
Chronical haloperidol Chronic Administration
and clozapine treatment
in rats
1131
of Drugs
The animals were kept under 12 hr light/l2 hr dark cycle with food and water ad libitum. Drug treated animals received either 1.6 mg/kg haloperidol received
tap water.
concentration
Water was sweetened
or 36 mg/kg clozapine in all groups
of 3% (w:v) to avoid taste variations
in their drinking water. Controls
by the addition
between
of sucrose
to the final
the drugs. The drinking
volume
was
examined every morning and every third day the body weight was controlled. Behavioral Tests The three groups of rats were subjected to behavioral test sessions in a standard open field. The tests were carried out at pretreatment
day three (control level) and at days two, nine, 16, and 23 of the chronic
treatment. The following parameters
were recorded during the trials: total distance moved (cm), velocity
(cm/s), number of rearings (n) and number of entries into the center (n). The open field arena consisted of dark-gray plastic with the bottom painted in ochre. It was divided into 25 squares (Al to E5) by gray lines. The arena measured
100 x 100 x 35 cm3. Diffuse illumination
200 cm above the field. Rats were transported
was provided by two 200 W-lamps,
within their home cages to the test room 1 hr before
starting the tests to minimize the influence of transportation
stress. The test room temperature
was 22°C.
After each trial, the test arena was carefully cleaned. For all tests, the path of each rat was registered automatically computer
by a computerized
combined
image analysis system. The hardware consisted
with a videodigitizer
acquisition and analysis was EthoVision@
(Noldus Information
The scores from the different treatment as the change to the respective
and a CCD video camera.
of an IBM-type
The software
Technology,
AT
used for data
Utrecht, Netherlands).
days were pooled for each group. The results were expressed
untreated
status. Statistically
significant
differences
were revealed by
Student’s t-test. Serum Concentrations
of Haloneridol
The rats were decapitated Serum was prepared determined
after 23 days of treatment in the morning and blood samples were collected.
by centrifugation
by a radioligand
were determined
and Clozanine
at 3200 g for 5 min. Haloperidol
serum concentrations
binding assay as described by Rao (1986). Clozapine
by HPLC with on-line
column
included adsorption of clozapine and its metabolites
switching
(Weigmann
on a cyanopropyl
were
serum concentrations
et al., 1997). The method
(CN) coated clean-up column (10
urn; 20 mm x 4.6 mm I. D.), and separation on Cl8 ODS Hypersil reversed phase material (5 urn; 250 mm x 4.6 mm I. D.). Ultraviolet-detection
was performed
at 254 nm.
V.
1132
Differential
RNA Display
After decapitation,
brains were immediately
each brain was isolated (Chomczynski
isothiocyanate-phenol-chloroform
and Sacci, 1987) with the modification
transcriptase
of an additional
(Promega,
Mannheim,
Germany).
(downstream
Oligo-dT
(Gene Ex Screen
Biomedicals, polyacrylamide
primers
with
two
additional
of the poly(A) tail. The second
with the same 3’primer and a second decamere arbitrary primer (upstream primer
Meckenheim,
of mRNA with MLV-
primers) (Gene Ex Screen primer Kit, Biometra,
Giittingen, Germany) were used to anchor the reaction to the beginning
primer)
method
DNAse clean up of the RNA
RNA display was the reverse transcription
in all possible combinations
step was PCR amplification
extraction
extraction.
The first step of the differential
nucleotides
removed and frozen in liquid nitrogen. Total RNA from
using the guanidinium
followed by phenol/chloroform
reverse
Fischer et al
Kit, Biometra)
Germany).
in presence
Amplification
gel. Gels were dried and exposed
of a-[“P]dATP,
300 Ci/mmol
(ICN
products were analysed on a nondenaturating for 1.5 hr to autoradiographic
6%
film (XAR2., Kodak,
Rochester, New York, U.S.A.). The differentially acetate, glycogen,
regulated bands were cut out of the gel. DNA was eluted, precipitated and ethanol and reamplified.
QIAEX II Gel Extraction
culture on agar supplemented selection.
samples were then purified using the
Kit (Quiagen, Hilden, Germany). The cDNA was cloned into the pCR-Script
SK(+) plasmid (Stratagene,
blue/white
The reamplified
with sodium
Heidelberg,
Germany).
with ampicilline
The positive clones were identified
(50 mg/l), X-Gal (80 mg/l) and IPTG (0.1 mM) by
Positive clones were grown overnight
plasmid DNA, inserts were PCR-amplified
in a Petri dish
in a multi well plate. After preparation
with primers specific to the insert-flanking
of
DNA stretches of
the plasmid. Inserts were then sequenced by a modified Sanger method (dye-dideoxy-termination). Data Analvsis The obtained sequences Biotechnology
were compared with the entries of the databases from the National Center for
Information
(NCBI),
e.g. European
Molecular
Biology
Laboratory
(EMBL),
NIH
Genetic Sequence Databases (GenBank) and DNA DataBank of Japan (DDBJ). The programs BLASTN and BLASTX
(Pearson
and Lipman,
1988) were used for the homology
comparison
between
the
queried and the database sequences.
Results Open Field Behavior Open field behavior of rats treated with haloperidol different parameters.
and clozapine
was analysed with respect to four
Total distance moved (cm) and velocity (cm/s) reflected the overall activity. The
Chronical haloperidol and clozapine treatment
1133
in rats
number of rearings (n) and of entries into the center (n) measured risk assessment. Rats treated with either haloperidol parameter
or clozapine
“distance moved” in comparison
showed a statistically
“velocity”, only the haloperidol
decrease (Fig. 1; t=2.93 p
“entries into the center” (t=4.26 p
“rearing?
by haloperidol
groups were compared
were significantly the difference
in the
t=2.57 ~~0.05; treated group
(t=6.46 p
but not by clozapine.
contrast, clozapine increased the number of rearings but this lacks statistical significance. treatment
reduction
to the control group (Fig. 1; haloperidol,
clozapine t=2.87 p
significant
In
When the two
with each other, the numbers of rearings and entries into the center
lower in the haloperidol
group (t=6.6 p
whereas
in distance moved and velocity did not reach statistical significance.
Fig 1. Shown are the changes compared to untreated conditions of the mean values of four test sessions during the neuroleptic treatment with either haloperidol or clozapine. Statistical significance is marked by an circle (0) for the comparison both at ~~0.05 (Student’s t-test).
to controls and by asterisk (*)
for intertreatment
comparison
for
V. Fischer et al
1134
Serum Concentrations From rats treated decapitation.
chronically
with
haloperidol
The receptor assay used for haloperidol
of 8 ng/ml. Clozapine serum levels determined Differential
blood
was obtained
after
showed mean serum concentrations
by HPLC revealed mean serum levels of 21 ngiml.
regulated bands have been identified by differential
These bands were obtained with the downstream primer (5’GGA downstream
of Bauer et al., 1993, these primers were termed
primer DlO and upstream primer U5, respectively. display gel, subcloned
and sequenced.
by haloperidol
with independent
shows a representative
One of these bands was cut out of the
The band consisted of two regulated gene fragments,
as well as by clozapine. The two sequences
281 bp and 266 bp. Reproducibility
of the results
cDNA preparations
RNA display analysis,
primer (5’-TTT TTT TTT TTA G-3’) and the upstream
ACC AAT C-3’). In the nomenclature
both dowmegulated
experiment
quantification
trunkal
RNA Display
To date, three differentially
differential
or clozapine,
was confirmed
obtained had a length of
by five-fold
replication
of the
and PCR reactions from each of the animals. Figure 2
gel image.
Discussion Behavioral Changes Behavior of rats treated chronically The behavioral differential
with either haloperidol
or clozapine was analysed in an open field.
changes after treatment with both neuroleptics
effects were consistent
atypical neuroleptic.
with the classification
indicated pharmacological
of the two substances
In the light of the main focus, the molecular
receptor
antagonists
“distance
moved”
was in line with behavioral
(Paulus and Geyer, confirms
the results
equivalent decrease in ambulation
as an either typical or
analysis of altered gene expression,
the animal numbers and the group sizes could be kept small. Nevertheless, overall activity under haloperidol
efficacy. The
the observed reduction of the
effects reported
for multiple dopamine
1991; Olivier et al., 1990). The decrease
in the parameter
of van den Buuse and den Jong (1989) who reported
scores in the open field after haloperidol
an
treatment in two different rat
strains. The other two parameters,
“number of rearings” and “entries into the center” are related to explorative
behavior and anxiety. In these parameters,
haloperidol
treated animals showed a significant
decrease
Chrontcal haloperidol
and clozaptne treatment
in rats
compared to controls whereas clozapine treatment resulted in an insignificant rearings.
Such a trend
observation haloperidol. changes
towards
of Bruhwyler However,
in activity.
increased
explorative
et al. (1990) who reported
anxiety
In addition,
and exploration
behavior
increase in the number of
was in line with the open
an anxiolytic
related
1135
parameters
potential
of clozapine
are potentially
field
but not of
confounded
it should be noted that the open field test is not specific
by
for the
evaluation of anxiety. In summary, the behavioral induce pharmacon-specific
examination
showed that the chronical treatment
regime was capable to
behavioral changes relevant to the clinical efficacy
Fig. 2. Representative 6% polyacrylamide differential RNA display gel. Amplification was carried out with the primer combination downstream primer DlO; upstream primer U5. The arrows mark the three differentially regulated gene fragments. K : cDNA of control animal, H : cDNA of haloperidol treated animal, C : cDNA of clozapine treated animal, M; marker.
1136
V. Fischer et aL
Serum Concentrations
of Haloperidol
Mean serum concentrations concentrations
and Clozanine
of haloperidol
in rats amounted to 8 ngiml. This was in the range of serum
of 5-12 ngiml found optimal for the therapy of schizophrenic
of clozapine in rats were 2 1 ng/ml. Clozapine
1992). Mean serum concentrations recommended
patients (van Putten et al.,
for the acute therapy
of schizophrenic
patients
serum concentrations
range between
350 and 450 ng/ml
(Hasegawa et al., 1993; Perry et al., 1991). However, one should be aware that clozapine is metabolised about 10 times faster in rats than in humans (Baldessarini pharmacological
effects
et al., 1993). Taken this and the observed
in the open field into consideration,
achieved were sufficiently
we concluded
that the serum levels
high to act on brain functions most propably related to psychic disorders.
Differential RNA Display Analysis The expression
of genes for dopamine
early transcription Meador-Woodruff
factors
receptors.
glutamate receptors,
have been shown to be modulated
neuropeptides
by neuroleptics
and immediate
(Marin et al., 1996;
et al., 1996: Waters et al., 1996; Mac Gibbon et al., 1994; Robertson
and Fibiger,
1992). This indicates that post receptor events bring about adaptive changes thought to be necessary for therapeutic effects. The clinical relevance of these distinct effects, however, is still a matter of debate. The method of differential
display enables a systematic
by drugs or other manipulations. based on the assumption mRNA molecules
The technique
was first described
that every cell expresses
can be reversely
transcribed
differential
RNA display
analysis
haloperidol
or clozapine
so far revealed
approach to identify genes that are regulated by Liang and Pardee (1992). It is
some 15,000 genes and that individual
and amplified
of brain RNA. obtained
by the polymerase
chain reaction.
from rats chronically
three differentially
regulated
species of Our
treated with either
bands. One of the bands was
further analysed and two gene fragments with a length of 28 1 bp and 266 bp were obtained. Both gene fragments
showed
fragments
were present
clozapine
treated rats. Therefore.
neuroleptics
the same regulatory
but markedly
they are suggested
or clozapine
downregulated
were conducted
some authors have expressed
In addition,
separately
the band chosen
treatment.
The
in the haloperidol
and
to be related to mechanisms concerned
RNA display (Liang et al., 1993). To minimize the possibility
clones. all experiments PCR reactions.
after either haloperidol
in the control animals
and their activity. However,
in differential
profile
common
about false positives
of obtaining false positive
with three different cDNA preparations
for subcloning
appeared
to both
to be regulated
in different in an on-off
fashion. The two regulated gene fragments showed no significant homology to entries in Gene Bank and EMBL data base so that we suppose that these sequences regions have not been cloned in rats so far.
represent genes whose 3’-prime untranslated
Chronical haloperidol
and clozapme treatment
1137
in rats
Conclusion In conclusion,
the study design that combined
may enable the systematic effects of neuroleptics
approach
behavioral,
to identify
pharmacokinetic
molecular
in an animal model. Our experiments
adaptive changes in the pharmacodynamic
events
and molecular
underlying
analysis,
pharmacotherapeutic
provide further evidence
for the role of
action of neuroleptics.
Acknowledgements The authors gratefully thank Professor blood plasma levels of haloperidol
Marie-Luise
Rao and Mrs. Gabriele Stroba for measuring
the
and clozapine, respectively
This study was supported by the Deutsche Forschungsgemeinschaft
(grant Da 37011-I)
References BALDESSARINI, R. J., CENTORRINO, F., FLOOD, J. G., VOLPICELLI, S. A., HUSTON-LYONS. D. and COHEN, B. M. (1993) Tissue Concentrations of Clozapine and its Metabolites in the Rat. Neuropsychopharmacol. 9: 117- 124. BARTHOLINI, G. (1976) Differential Effects of Neuroleptic Drugs on Dopamine Extrapyramidal and Limbic Systems. J. Pharm. Pharmacol. 3: 429-433.
Turnover
in the
BAUER, P., MULLER, H., REICH, J., RIEDL, H., AHRENKIEL, V., WARTHOE, P. and STRAUSS. M. (1993) Identification of Differentially Expressed mRNA Species by an Improved Display Technique (DDRT-PCR). Nut. Acid. Res. a: 4272-4280. BRUHWYLER, J., CHLEIDE, E., LIEGEOIS, Anxiolytic Potential of Sulpiride, Clozapine Biochem. Behav. 36: 57-61.
J. F., DELARGE, J. and MERCIER, M. (1990) and Derivates in the Open-Field Test. Pharmacol.
CHOMCZYNSKI, P. and SACCHI, N. (1987) Single-Step of RNA Isolation Thiocyanate-Phenol-Chloroform Extraction. Ana. Biochem. 162: 156-159.
by Acid Guanidinium
HASEGAWA, M., GUTIERREZ-ESTEINOU, R., WAY, L. and MELTZER, H. Y. (1993) Relationship Between Clinical Efficacy and Clozapine Concentrations in Plasma in Schizophrenia: Effect of Smoking. J. Clin. Psychopharmacol. 12: 383-390. JANSSEN, P. A. J., VAN DE WESTERINGH, C., JAGENAU. A. H. M., DEMOEN, P. A. J., HERMANS, B. K. F., VAN DAELE, G. H. P., SCHELLEKENS, K. H. L., VAN DER EYCKEN, C. A. M. and NIEMEGEERS, C. J. E. (1959) Chemistry and Pharmacology of CNS Depressants Related to 4-(4-Hydroxy-4-Phenylpiperidino)-Butyrophenone. Part 1 - Synthesis Acid Screening Data in Mice. J. Med. Pharm. Chem. L: 281-297. KERWfN, R. W. (1994) The New Atypical Antipsychotics.
British J. Psychiat. 164: 141-148.
LEYSEN, J. E., JANSSEN, P., GOMMEREN, W., WYNANTS, J., PAUWELS. P. J. and JANSSEN, P. A. J. (1992) In Vitro and In Vivo Binding and Effects on Monoamine Turnover in Rat Brain Regions of the Novel Antipsychotics Risperidone and Ocaperidone. Mol. Pharmacol. 4-l: 494-508. LIANG, P. and PARDEE, A. B. (1992) Differential Display of Eukaryotic Messenger of the Polymerase Chain Reaction. Science 257: 967-97 1.
RNA by Means
1138
V. Fischer et al.
LIANG, P., AVERBOUKH, L. and PARDEE, A. B. (1993) Distribution and Cloning of Eukaryotic mRNAs by Means of Differential Dislay: Refinements and Optimization. Nut. Acid. Res. 2-l: 32693275. MAC GIBBON, G. A., LAWLOR, P. A., BRAVO, R. and DRAGUNOW, M. (1994) Clozapine and Haloperidol Produce a Differential Pattern of Immediate Early Gene Expression in Rat CaudatePutamen, Nucleus Accumbens, Lateral Septum and Islands of Calleja. Mol. Brain Res. 23: 21-32. MARIN, C., ENGBER, T. M., BONASTRE, M., CHASE, T. N. and TOLOSA, T. (1996) Effect of Long-Term Haloperidol Treatment on Striatal Neuropeptides: Relation to Stereotyped Behavior, Brain Res. 73: 57-62. MEADOR-WOODRUFF. J. H., KING, R. E., DAMASK. S. P. and BOVENKERK, K. A. (1996) Differential Regulation of Hippocampal AMPA and Kainate Receptor Subunit Expression by Haloperidol and Clozapine. Mol. Psychiat. L: 41-53. NESTLER, E. J. (1997) Images in Neuroscience. Transcription Factors. Am. J. Psychiat. 154: 146.
Molecular
Biology,
IV.
Identifying
DNA
NIELSEN, E. B. and Andersen P. H. (1992) Dopamine Receptor Occupancy in Vivo: Behavioral Correlates Using NNC-112, NNC-687 and NNC-756. New Selective Dopamine Dl Receptor Antagonists. Eur. J. Pharmacol. 219: 35-44. OLIVIER, B., MOS, J. and RASMUSSEN. D. (1990) Behavioural Eltoprazine. Drug Metabol. Drug Interact. 8: 3 l-83. PEARSON, W. R. and LIPMAN D. J. (1988) Improved Proc. Natl. Acad. Sci. USA a: 2444-2448.
Pharmacology
Tools for Biological
of the Serenic,
Sequence
Comparison.
PAULUS. M. P. and GEYER, M. A. (199 1) A Scaling Approach to Find Order Parameters Quantifying the Effects of Dopaminergic Agents on IJnconditioned Motor Activity in Rats. Prog. Neuropsychopharmacol. Biol. Psychiat. 15: 903-919. PERRY, P. J., MILLER, D. D., ARNDT, S. V. and CADORE?‘. R. J. (1991) Norclozapine Plasma Concentrations and Clinical Response of Treatment-Refractory Patients. Am. J. Psychiat. 148: 23 l-235.
Clozapine and Schizophrenic
PILOWSKY, L. S., COSTA, D. C., ELL, P. J., MURRAY. R. M., VERHOEFF, N. P. and KERWIN. R. W. (1992) Clozapine, Single Photon Emission Tomography, and the D2 Dopamine Receptor Blockade Hypothesis of Schizophrenia. Lancet 340: 199-202. RAO, M. L. (1986) Modification of the Radioreceptor Assay Technique for Estimation Neuroleptic Drug Levels Leads to Improved Precision and Sensitivity. Psychopharmacol. 553.
of Serum 90: 54%
ROBERTSON, G. S. and FIBIGER, H. C. (1992) Neuroleptics Increase c-fos Expression Forebrain: Contrasting Effects of Haloperidol and Clozapine. Neurosci. 46: 3 15-328. SETTLE, E. C. Jr. and AYD F. J. Jr. (1983) Haloperidol: Psychiat. 44: 440-448.
A Quarter Century of Experience.
in the J. Clin.
VAN DEN BUUSE, M. and DE JONG, W. (1989) Differential Effects of Dopaminergic Drugs on Open-Field Behavior of Spontaneously Hypersensitive Rats and Normotensive Wistar-Kyoto Rats. J. Pharmacol. Exp. Ther. 248: 1189-I 196. VAN PIJTTEN, T., MARDER, Levels and Clinical Response:
S. R.. MINTZ. J. and POLAND, R. E. (1992) Haloperidol Plasma A Therapeutic Window Relationship. Am. J. Psychiat. 149: 500-505.
Chronical haloperidol and clozapine treatment in rats
1139
VAN TOL, H. H., BRUNZOW, J. R., GUAN, H. C., SUNAHARA, R. K., SEEMAN, P., NIZNIK, H. B. and CIVELLI, 0. (1991) Cloning of the Gene for a Human Dopamine D4 Receptor with High Affinity for the Antipsychotic Clozapine. Nature 350: 610-614. WATERS, S. M., KONOKOY, C. S. and DAVIS, T. P. (1996) Haloperidol and Apomorphine Differentially Affect Neuropeptidase Activity. J. Pharmacol. Exp. Ther. 277: 113-120. WEIGMANN, H., BIERBRAUER, J., HARTTER, S. and HIEMKE, C. (1997) Automated Determination of Clozapine and Major Metabolites in Serum and Urine. Therap. Drug Monit. 19: 480-488. WEINER, I., SHADACH, E., TARRASCH, R., KIDRON, R. and FELDON, J. (1996) The Latent Inhibition Model of Schizophrenia: Further Validation Using the Atypical Neuroleptic, Clozapine. Biol. Psychiat. 40: 834-843.
Inquiries and reprint requests should be addressed to: Prof. Dr. Christoph Hiemke Department of Psychiatry University of Mainz Untere ZahlbacherstraBe 8 55 13 1 Mainz, Germany